Literature DB >> 24916985

Atypical cutaneous leishmaniasis in the immunosuppressed.

Clayton Micallef1, Charles Mallia Azzopardi2.   

Abstract

A 45-year-old woman, known case of seronegative arthritis and on immunosuppressive therapy, presented with a 2-week history of a macular lesion on the left calf that became papular and eventually ulcerated. The rest of the history was otherwise unremarkable and systemic examination did not reveal any abnormalities. The lesion was repeatedly biopsied but failed to reveal Leishmania donovani bodies. Concurrent Leishmania IgG was positive but IgM was negative. Leishmania IgG confirmatory testing by ELISA was negative. A biopsy from the lesion eventually tested positive for L. donovani through PCR. The patient was treated with sodium stibogluconate together with intravenous ciprofloxacin and amoxicillin to cover the secondary cutaneous bacterial infection. This led to complete resolution of the lesion. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24916985      PMCID: PMC4054259          DOI: 10.1136/bcr-2014-204914

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe.

Authors:  P Zanger; I Kötter; P G Kremsner; S Gabrysch
Journal:  Clin Microbiol Infect       Date:  2011-10-10       Impact factor: 8.067

Review 2.  Leishmaniasis.

Authors:  T V Piscopo; A C Mallia
Journal:  Postgrad Med J       Date:  2006-10       Impact factor: 2.401

3.  The histopathology of cutaneous leishmaniasis due to Leishmania (Leishmania) mexicana in the Yucatan peninsula, Mexico.

Authors:  Fernando J Andrade-Narvaez; Salvador Medina-Peralta; Alberto Vargas-Gonzalez; Silvia B Canto-Lara; Sergio Estrada-Parra
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2005-08-29       Impact factor: 1.846

4.  Cutaneous leishmaniasis with histopathologic pattern of non-necrotizing granulomatous dermatitis in patients treated with adalimumab.

Authors:  Alberto Romero-Maté; Diego Martínez-Sánchez; Juan C Tardío; Amalia Moreno-Torres; Carmen García-Donoso; Marta Aguado-Lobo; Pablo Espinosa-Lara; Jesús Borbujo
Journal:  Dermatol Online J       Date:  2012-09-15

5.  Polymerase chain reaction for diagnosis of cutaneous leishmaniasis in histologically positive, suspicious and negative skin biopsies.

Authors:  Akbar Safaei; Mohammad Hossein Motazedian; Mohammad Vasei
Journal:  Dermatology       Date:  2002       Impact factor: 5.366

6.  PCR detection of Leishmania in skin biopsies.

Authors:  Meryem Lemrani; Salsabil Hamdi; Abderahmane Laamrani; Mohammed Hassar
Journal:  J Infect Dev Ctries       Date:  2009-09-15       Impact factor: 0.968

7.  Leishmaniasis in the era of tumor necrosis factor alpha antagonist therapy--a research agenda for Europe.

Authors:  P Zanger; S Gabrysch
Journal:  Euro Surveill       Date:  2013-07-25

Review 8.  Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe.

Authors:  Ioannis D Xynos; Maria G Tektonidou; Dimitrios Pikazis; Nikolaos V Sipsas
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

9.  Molecular identification of leishmania species using samples obtained from negative stained smears.

Authors:  Ma Mohaghegh; A Fata; Gh Salehi; F Berenji; M Mousavi Bazzaz; H Rafatpanah; M Parian; A Movahedi
Journal:  Iran J Parasitol       Date:  2013-04       Impact factor: 1.012

  9 in total
  2 in total

1.  Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression.

Authors:  Pau Bosch-Nicolau; Maria Ubals; Fernando Salvador; Adrián Sánchez-Montalvá; Gloria Aparicio; Alba Erra; Pablo Martinez de Salazar; Elena Sulleiro; Israel Molina
Journal:  PLoS Negl Trop Dis       Date:  2019-08-30

2.  Nonconventional opponents: a review of malaria and leishmaniasis among United States Armed Forces.

Authors:  Kaylin J Beiter; Zachariah J Wentlent; Adrian R Hamouda; Bolaji N Thomas
Journal:  PeerJ       Date:  2019-01-25       Impact factor: 2.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.